SentiBioLogo.jpg
Senti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy
July 01, 2024 08:05 ET | Senti Biosciences, Inc.
The California Institute for Regenerative Medicines (CIRM) has awarded an $8 million grant to Senti Bio to support clinical development of SENTI-202.
finacialnews-logo-final-01 (2).png
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
June 17, 2024 09:45 ET | FN Media Group LLC
PALM BEACH, Fla., June 17, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - According to a report from Mordor Intelligence the Acute Myeloid Leukemia Market size is estimated at USD 1.83...
finacialnews-logo-final-01 (2).png
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
June 17, 2024 09:00 ET | FN Media Group LLC
PALM BEACH, Fla., June 17, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Acute Myeloid Leukemia (AML) is a type of cancer that affects the blood and bone marrow. It is characterized by...
Q Assist, New Context Aware Generative AI Technology Suite from Quantexa
Quantexa Debuts Q Assist, New Context Aware Generative AI Technology Suite
June 10, 2024 02:18 ET | Quantexa
New AI advancements are helping industry leaders get data ready for AI and make impact
Kura Oncology Logo
Kura Oncology to Participate in Jefferies Global Healthcare Conference
May 29, 2024 07:30 ET | Kura Oncology, Inc.
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...
Aptose Biosciences Inc. logo
Aptose Reports Results for the First Quarter 2024
May 14, 2024 16:01 ET | Aptose Biosciences, Inc.
Aptose Reports Results for the First Quarter 2024
Kura Oncology Logo
Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML
May 14, 2024 07:30 ET | Kura Oncology, Inc.
– Company enrolls 85 patients with R/R NPM1-mutant AML in fewer than 16 months – – Topline data expected in early 2025 – – Breakthrough Therapy Designation to enable expedited review by FDA – SAN...
SentiBioLogo.jpg
Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
May 13, 2024 08:15 ET | Senti Biosciences, Inc.
Senti Bio today announced that patient dosing has commenced in the Phase 1 clinical trial of SENTI-202.
SentiBioLogo.jpg
Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights
May 09, 2024 16:05 ET | Senti Biosciences, Inc.
Senti Biosciences, Inc. (Nasdaq: SNTI) today reported operational updates and financial results for the first quarter of 2024.
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update
May 09, 2024 16:05 ET | Vor Biopharma
On-track for trem-cel and VCAR33ALLO clinical updates in the second half of 2024Trem-cel trial expanded to include patients with myelodysplastic syndromes (MDS); Mylotarg™ dosing has advanced to the...